U.S. markets open in 2 hours 38 minutes

Viatris Inc. (VTRS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
13.84-0.08 (-0.57%)
At close: 4:00PM EDT
13.90 +0.06 (0.43%)
Pre-Market: 06:09AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close13.92
Open13.87
Bid0.00 x 40700
Ask0.00 x 4000
Day's Range13.78 - 14.06
52 Week Range12.94 - 18.86
Volume3,965,032
Avg. Volume8,220,579
Market Cap16.728B
Beta (5Y Monthly)1.50
PE Ratio (TTM)N/A
EPS (TTM)-2.23
Earnings DateAug 09, 2021
Forward Dividend & Yield0.44 (3.18%)
Ex-Dividend DateMay 21, 2021
1y Target Est19.93
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • 3 Stocks to Buy Whether or Not a Market Crash Is Near
    Motley Fool

    3 Stocks to Buy Whether or Not a Market Crash Is Near

    Maybe the market is about to crash, and maybe it isn't. These stocks look like good picks either way.

  • 3 Things Every Investor Should Know About Pfizer's Dividend
    Motley Fool

    3 Things Every Investor Should Know About Pfizer's Dividend

    Here are three things every investor should know about Pfizer's dividend. Only six of them have dividend yields that are higher than Pfizer's yield of 3.9%. This inverse relationship makes Pfizer's dividend yield stand out even more.

  • Pfizer To Pay $345M To Resolve EpiPen Pricing Lawsuit: Reuters
    Benzinga

    Pfizer To Pay $345M To Resolve EpiPen Pricing Lawsuit: Reuters

    Pfizer Inc (NYSE: PFE) has agreed to pay $345 million to resolve claims by consumers claiming they overpaid for EpiPens due to anti-competitive and unfair practices, reports Reuters. The proposed class action settlement was disclosed in a filing in federal court in Kansas City, Kansas. The deal, which requires a judge's approval, would not resolve claims against Mylan, which is scheduled to face trial in January. Pfizer, which did not admit wrongdoing, did not immediately respond to a request fo